Bruker Acquires Prolab Instruments to Augment Multiomics Solutions

Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) has acquired Prolab Instruments GmbH, a Swiss firm specializing in high-precision low-flow liquid chromatography technology. This acquisition is expected to enhance Bruker’s capabilities in proteomics and metabolomics, integrating Prolab's unique Zirconium™ products, including the Zirconium Qube autosampler and Zirconium Ultra UHPLC systems. Prolab's innovations will improve high-performance mass spectrometry workflows, particularly for single-cell proteomics, validating Bruker's strategy in expanding its analytical solutions portfolio.

Positive

• Acquisition of Prolab enhances Bruker's proteomics and metabolomics capabilities.
• Integration of Prolab's Zirconium™ technology supports high-performance mass spectrometry.
• Potential for improved product innovation and faster market delivery.

Negative

• None.

Prolab precision pumps, autosamplers and nano-flow to cap-LC UHPLC systems to further enhance performance and robustness of timsTOF 4D proteomics and metabolomics solutions

• Unique Zirconium™ nano-LC to cap-LC pump technology for 4 nL/min to 10 μL/min flow rates with split-less UHPLC operation for optimized proteomics results
• Innovative, proprietary Zirconium Cube™ autosampler with mobile injection unit technology for precise, ultra-low volume injections in high sensitivity single-cell proteomics and immunopeptidomics
• ZircoFIT™ UHPLC fittings for robust, easy-to-use nano- to cap-LC fused silica connections to enhance chromatographic peak shapes
• New Zirconium™ Ultra UHPLC System for cap-LC high-throughput proteomics and metabolomics

BILLERICA, Mass.--(BUSINESS WIRE)--

Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Prolab Instruments GmbH, a Swiss technology company specialized in low-flow, high precision liquid chromatography technology and systems. Financial terms of the transaction were not disclosed.

Zirconium Ultra for cap-LC high-throughput 4D proteomics and metabolomics

Established in 1988, ProLab’s innovations center around micro and nano-UHPLC pump technology, resulting in the development of the unique Zirconium™ split-less pump technology for flow rates from nano-flow (4-800 nL/min) to cap-flow (1-10 µL/min) regimes. The Zirconium™ Ultra nano- and cap-UHPLC system supports a broad range of flow rates from 4 nL/min to 10 µL/min at 1000 bar (15,000 psi), and is suitable for cap-LC in high-throughput proteomics and metabolomics.

Recently, Prolab launched the innovative Zirconium Qube autosampler with the proprietary mobile injection unit technology that integrates the injector valve and loop, and moves to each sample vial to minimize carry-over, thereby enabling ultra-low volume injections with high precision. This unique high-precision injection capability has potential to further enhance single cell proteomics.

Leveraging nearly 30 years of experience with low flow rates and minimized dead volumes, Prolab also offers unique Zircofit™ fused silica connectors known for flexibility, robustness and ease of use.

Mr. Werner Doebelin, the Founder and CEO of Prolab, said: “We are pleased to become part of Bruker and augment the proteomics and metabolomics workflows of high-performance mass spectrometry systems like the timsTOF or scimaX® MRMS platforms. Our Zirconium pump is already part of the Bruker high-performance nanoElute system. Being part of Bruker allows us to increase the pace of product innovation, and we are looking forward to bringing our Mobile Injection Unit Technology to market to further improve performance and robustness in key applications, like single cell proteomics and lipidomics.”

Mr. Juergen Srega, the President of the Bruker CALID Group, explained: “Given the enormous sensitivity improvements of our timsTOF Pro 2 and timsTOF SCP mass spectrometers, our customers are working with lower and lower sample amounts. Prolab’s innovative mobile injector technology on the Zirconium Qube autosampler provides high-precision, low volume injections with minimal sample loss and carryover, as well as faster cycle times. Zirconium perfectly complements our ultra-high sensitivity unbiased, deep 4D proteomics, immunopeptidomics and single-cell proteomics solutions.”

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005084/en/

Media:

Petra Scheffer

Bruker Daltonics Marketing Communications

T: +49 (421) 2205-2843

E: petra.scheffer@bruker.com

Investors:

Bruker Investor Relations

T: +1 (978) 663-3660, ext. 1479

E: Investor.Relations@bruker.com

Source: Bruker Corporation

FAQ

What acquisition did Bruker announce?

Bruker announced the acquisition of Prolab Instruments GmbH, a Swiss company specializing in liquid chromatography technology.

What technology does Prolab contribute to Bruker?

Prolab contributes its Zirconium™ nano and cap-LC systems, enhancing Bruker's proteomics and metabolomics workflows.

How will the acquisition impact Bruker's product offerings?

The acquisition is expected to improve the performance and robustness of Bruker's mass spectrometry solutions in proteomics and metabolomics.

When was the acquisition of Prolab made public?

The acquisition was publicly announced on January 19, 2022.